LC-MS Approach for Comprehensive Monophosphoramidite Prodrug Monitoring in Human Plasma

Current research initiatives constitute a multifaceted approach to address the complexities of the pandemic, involving the study of an antiviral drug known as Mono Phosphoramidite pro drug, pharmacological investigations, and advanced diagnostics. Analytical methods for detecting and quantifying antiviral compounds have also evolved over the past decade, with relevance to COVID-19 treatment. This research critically assesses sample pre-treatment and extraction methods, detection and quantification techniques, and methods with preliminary separation steps. The major goal of this study is to contribute scientific solutions against SARS-CoV-2 and mitigate its detrimental effects. The goal is to reliably detect Mono Phosphoramidite pro drug at low concentrations in human plasma, facilitating its quantification in therapeutic drug tracking and pharmacokinetic investigation. The subsequent validation process will assess the method's accuracy, precision, linearity, sensitivity, selectivity, and stability, adhering to international regulatory guidelines for quantitative analysis in clinical and research settings. Successful development and validation of this LC-MS/MS method will significantly contribute to ongoing research and clinical use of mono phosphoramidite pro drug (Remdesivir). It will enable the determination of pharmacokinetic parameters, aid in dose optimization, and support safe and effective patient administration. This robust bioanalytical method will ultimately enhance our understanding of the Mono Phosphoramidite pro drug's pharmacological properties and improve its therapeutic application of infectious diseases.